Clinical Trials Logo

Clinical Trial Summary

Primary objective:

*To determine whether treatment with naloxone hydrochloride nasal spray reduces gambling urge symptoms in patients with gambling disorder

The secondary objectives of the study are:

- To determine the effects of naloxone hydrochloride nasal spray on gambling severity, frequency and time, internet use, self-efficacy, quality of life, alcohol consumption, depression

- To evaluate the safety of naloxone hydrochloride nasal spray in the treatment of gambling disorder


Clinical Trial Description

This is a 12 week, randomised, double-blind, placebo-controlled, parallel group study to determine the efficacy of naloxone hydrochloride nasal spray in gambling disorder. Anticipated number of participants are 126.

Treatment Group A: Naloxone hydrochloride 40mg/ml nasal spray Naloxone hydrochloride will be dosed at 4mg / dose (one spray of 0.1ml of the 40mg/ml formulation into one nostril) up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Treatment Group B: Placebo nasal spray One spray of 0.1ml of the placebo formulation in one nostril up to four times daily as needed in response to gambling urges with at least 2 hours between each dose (within 24 hours from 6am each day) for 12 weeks.

Safety parameters:

Study Subjects will be asked to report any changes in health via the daily questionnaire. This will be reviewed weekly and at each study Visit (including phone calls) and any adverse events will be documented in the eCRF. Changes in vital signs and outcome of routine blood analyses will be evaluated.

Adverse events (AEs) will be classified using a coding thesaurus (MedDRA).

Primary endpoint: Gambling symptoms (G-SAS) from Baseline to week 12. Gambling symptoms (G-SAS) from Baseline to week 12. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT03430180
Study type Interventional
Source National Institute for Health and Welfare, Finland
Contact
Status Enrolling by invitation
Phase Phase 2
Start date February 22, 2018
Completion date March 30, 2020

See also
  Status Clinical Trial Phase
Completed NCT02590211 - Poker, Skills and Associated Problems N/A
Completed NCT02203786 - D1 and D2 Dopamine Receptors in Gambling and Amphetamine Reinforcement Phase 2
Completed NCT05051085 - Feasibility of the Internet-delivered Treatment "SpilleFri" for Patients With Pathological Gambling N/A
Completed NCT01215357 - Clinical Study to Determine if Ecopipam Can Reduce Urges to Gamble Phase 2
Terminated NCT00245583 - Topiramate in the Treatment of Pathological Gambling Phase 3
Completed NCT04842461 - Mental Health, Addictions and Biomarkers in High Athletes Performance
Not yet recruiting NCT03280966 - Effects of Intranasal Naloxone on Gambling Urges in Gambling Disorder Phase 2
Active, not recruiting NCT01743092 - Testing Resources: Manual and Webinar Guided Treatment vs. Manual Guided Treatment N/A
Active, not recruiting NCT01528982 - Susceptibility to Pathological Gambling N/A
Terminated NCT00211822 - Functional Magnetic Resonance Imaging (fMRI) Studies in Pathological Gambling (PG) and Obsessive-Compulsive Disorder (OCD) N/A
Completed NCT01381250 - Effects of Internet-based Treatment of Pathological Gambling N/A
Completed NCT05506384 - Treatment Study for Problematic Gaming and Gambling N/A
Enrolling by invitation NCT03464838 - Effects of Transcranial Direct Current Stimulation (tDCS) in Gambling Disorder N/A
Terminated NCT01560351 - Repeated Low-frequency Transcranial Magnetic Stimulation Reduces Cue-induced Craving: a Randomized, Prospective, Double-blind, Sham-controlled, Cross-over Study N/A
Completed NCT00580567 - Impulsivity in Pathological Gambling N/A
Completed NCT02240485 - Integrative Couple Treatment for Pathological Gambling N/A
Withdrawn NCT01340274 - Community Reinforcement Approach and Family Training (CRAFT) for Problem Gambling Phase 2
Recruiting NCT02491996 - The Efficacy of Therapy Focused on Desire-satisfaction for Disordered Gamblers N/A
Recruiting NCT01154712 - Deep Low-Frequency Repetitive Transcranial Magnetic Stimulation for Cessation of Pathological Gambling Phase 1
Completed NCT01843699 - Topiramate Trial for Pathological Gamblers Phase 2